Summary:
Pfizer on Monday announced a study to explore coadministration of its pneumococcal vaccine along with a third dose of the Pfizer-BioNTech Covid-19 vaccine in older adults. Pfizer CEO Albert Bourla had announced that Covid vaccine recipients will “likely” need a third dose between six to 12 months after they're fully vaccinated. The company is now testing a third booster shot of its vaccine on fully vaccinated people. US pharmaceutical Moderna in its Phase 2 study found that a third booster shot of its Covid vaccine can rapidly increase the level of antibodies in previously inoculated people. The 20vPnC candidate vaccine is in development for the prevention of invasive disease and pneumonia caused by 20 serotypes of Streptococcus pneumoniae in the vaccine in adults ages 18 years and older..